Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities.

Yao Y, Chen L, Wei W, Deng X, Ma L, Hao S.

Biochem Biophys Res Commun. 2013 Jun 21;436(1):60-5. doi: 10.1016/j.bbrc.2013.05.058.

PMID:
23707941
2.
3.
5.

CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.

Zhang H, Xie Y, Li W, Chibbar R, Xiong S, Xiang J.

Cell Mol Immunol. 2011 Jan;8(1):23-30. doi: 10.1038/cmi.2010.59.

6.

Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.

Lee YS, Kim SH, Cho JA, Kim CW.

Exp Mol Med. 2011 May 31;43(5):281-90. doi: 10.3858/emm.2011.43.5.029.

7.

Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.

Xie Y, Zhang H, Li W, Deng Y, Munegowda MA, Chibbar R, Qureshi M, Xiang J.

J Immunol. 2010 Nov 1;185(9):5268-78. doi: 10.4049/jimmunol.1000386.

8.

Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.

Parameswaran S, Khalil M, Ahmed KA, Sharma RK, Xiang J.

Tumori. 2015 Nov-Dec;101(6):637-43. doi: 10.5301/tj.5000297.

PMID:
25983089
9.
10.

Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.

Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q, Cao X.

Eur J Immunol. 2006 Jun;36(6):1598-607.

11.

Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.

Xie Y, Bai O, Zhang H, Li W, Xiang J.

Cancer Biother Radiopharm. 2010 Feb;25(1):21-8. doi: 10.1089/cbr.2009.0714.

PMID:
20187793
12.

Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.

Xie Y, Zhang X, Zhao T, Li W, Xiang J.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):152-5. doi: 10.1016/j.bbrc.2013.07.044.

PMID:
23876314
13.

Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.

Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Xiang J.

Vaccine. 2012 May 21;30(24):3519-25. doi: 10.1016/j.vaccine.2012.03.075.

PMID:
22484292
14.

Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.

Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, Slattery K, Qureshi M, Wei Y, Deng Y, Xiang J.

J Cell Mol Med. 2010 Nov;14(11):2655-66. doi: 10.1111/j.1582-4934.2009.00851.x.

15.

Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein.

Lacave R, Masurier C, Guigon M, Lemoine FM, Klatzmann D, Colombo BM.

Int J Oncol. 2003 Dec;23(6):1747-53.

PMID:
14612950
16.

Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity.

Hao S, Ye Z, Yang J, Bai O, Xiang J.

Cancer Biother Radiopharm. 2006 Apr;21(2):146-54.

PMID:
16706635
17.
18.

GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.

Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Chibbar R, Wei Y, Liu Q, Xiang J.

Vaccine. 2011 Apr 27;29(19):3538-47. doi: 10.1016/j.vaccine.2011.02.095.

PMID:
21406265
19.

CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.

Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J.

J Immunol. 2009 Jan 1;182(1):193-206.

20.

Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine.

Chen T, Guo J, Yang M, Zhu X, Cao X.

J Immunol. 2011 Feb 15;186(4):2219-28. doi: 10.4049/jimmunol.1002991.

Items per page

Supplemental Content

Support Center